Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Barton

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Molecular Graphics & Modelling|November 16, 2010
A rapid computational filter for predicting the rate of human renal clearanceStuart W Paine, Patrick Barton, James Bird, et al.
Biomaterials and Biosystems|February 24, 2023
Setup of human liver-chips integrating 3D models, microwells and a standardized microfluidic platform as proof-of-concept study to support drug evaluationBenoit Cox, Patrick Barton, Reiner Class, et al.
Journal of the American Society for Mass Spectrometry|March 12, 2025
Spatial Distribution of Brain PET Tracers by MALDI ImagingIsabeau Vermeulen, Michiel Vandenbosch, Delphine Viot, et al.
Neurobiology of Disease|April 4, 2024
Spatial omics reveals molecular changes in focal cortical dysplasia type IIIsabeau Vermeulen, Natalia Rodriguez-Alvarez, Liesbeth François, et al.
Journal of Medicinal Chemistry|July 11, 2003
QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonistsRupert P Austin, Patrick Barton, Roger V Bonnert, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2012
The discovery of CCR3/H1 dual antagonists with reduced hERG riskAsh Bahl, Patrick Barton, Keith Bowers, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092Ash Bahl, Patrick Barton, Keith Bowers, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2007
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosisBrian Springthorpe, Andrew Bailey, Patrick Barton, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Molecular Graphics & Modelling|November 16, 2010
A rapid computational filter for predicting the rate of human renal clearanceStuart W Paine, Patrick Barton, James Bird, et al.
Biomaterials and Biosystems|February 24, 2023
Setup of human liver-chips integrating 3D models, microwells and a standardized microfluidic platform as proof-of-concept study to support drug evaluationBenoit Cox, Patrick Barton, Reiner Class, et al.
Journal of the American Society for Mass Spectrometry|March 12, 2025
Spatial Distribution of Brain PET Tracers by MALDI ImagingIsabeau Vermeulen, Michiel Vandenbosch, Delphine Viot, et al.
Neurobiology of Disease|April 4, 2024
Spatial omics reveals molecular changes in focal cortical dysplasia type IIIsabeau Vermeulen, Natalia Rodriguez-Alvarez, Liesbeth François, et al.
Journal of Medicinal Chemistry|July 11, 2003
QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonistsRupert P Austin, Patrick Barton, Roger V Bonnert, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2012
The discovery of CCR3/H1 dual antagonists with reduced hERG riskAsh Bahl, Patrick Barton, Keith Bowers, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092Ash Bahl, Patrick Barton, Keith Bowers, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2007
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosisBrian Springthorpe, Andrew Bailey, Patrick Barton, et al.
Pageof 3